[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636658":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":22,"locations":22,"responsibleParty":23,"collaborators":22,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":27,"sex":33,"minAge":34,"maxAge":35,"enrollmentInfo":36,"targetDuration":22,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":49,"overallStatus":57,"whyStopped":22,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":22},{"fullName":5,"class":6},"Nakhia Impex LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HA35 Nasopharyngeal Care Gel Intervention Group","EXPERIMENTAL","Participants will receive 13.6% high-concentration 35 kDa hyaluronan (HA35) nasopharyngeal care gel, administered via the nasopharyngeal route, one unit per nostril, twice daily (morning and evening) for 10 consecutive days. The intervention is non-pharmacological and designed to evaluate efficacy and safety in subjects with chronic rhinitis and chronic pharyngitis.",[13],"Device: 13.6% High-Concentration 35 kDa Hyaluronan (HA35) Nasopharyngeal Care Gel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","13.6% High-Concentration 35 kDa Hyaluronan (HA35) Nasopharyngeal Care Gel","A topical, non-pharmacological nasopharyngeal care gel containing 13.6% high-concentration 35 kDa hyaluronan. It is designed to support mucosal hydration and reduce inflammation in the nasopharynx. Administration is via direct nasopharyngeal application, twice daily for 10 consecutive days.",[9],[21],"HA35 Nasopharyngeal Gel; HA35 Care Gel",null,{"type":24,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100636658","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-chronic-nasopharyngitis-100636658",false,"NCT07568548","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Chronic Nasopharyngitis","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate Efficacy and Safety of Topical 10% 35 kDa Hyaluronan (HA35) Gel for Ultra-Rapid Relief of Skin Pruritus","HA35","Inclusion Criteria:\n\n* Age 18-80 years, male or female\n* Clinically diagnosed with chronic rhinitis and chronic pharyngitis for ≥3 months\n* Baseline nasopharyngeal discomfort NRS score ≥4 points\n* Baseline posterior pharyngeal discomfort NRS score ≥4 points\n* Voluntary participation and signed written informed consent\n* Ability to complete symptom assessment independently\n\nExclusion Criteria:\n\n* Acute upper respiratory tract infection within 2 weeks\n* Use of antihistamines, intranasal corticosteroids, decongestants, or other nasal medications within 2 weeks prior to screening\n* History of nasal\u002Fsinus surgery within 6 months\n* Known hypersensitivity to hyaluronan or any gel ingredients\n* Pregnant or lactating women\n* Severe systemic diseases or malignant tumors","ALL","18 Years","80 Years",{"count":37,"type":38},30,"ESTIMATED","INTERVENTIONAL",[41],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of nasopharyngeal administration of 13.6% high-concentration 35 kDa hyaluronan (HA35) care gel in subjects with chronic rhinitis and chronic pharyngitis. Eligible participants will receive the study gel twice daily for 10 consecutive days. The primary objectives are to assess rapid changes in nasopharyngeal discomfort, posterior pharyngeal discomfort, and nasal obstruction within 30 minutes after the first administration. Secondary objectives include evaluation of overall symptom improvement at day 10, changes in subjective mental clarity, and safety and tolerability throughout the treatment period. This is a minimal-risk, non-pharmacological supportive care intervention.",[44,45,46,47,48],"Chronic Rhinitis","Chronic Pharyngitis","Nasopharyngitis","Posterior Pharyngeal Inflammation","Nasal Obstruction",[50,51,31,52,44,45,53,54,55,56],"Hyaluronan","35 kDa Hyaluronan","Nasopharyngeal Care","Nasal Congestion","Pharyngeal Discomfort","Non-pharmacological Intervention","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":60,"type":61},"2026-05-08","ACTUAL",{"date":63,"type":38},"2026-05-01",{"date":65,"type":38},"2026-07-01",{"name":5,"class":6}]